The brand’s products provide a safe and healthy alternative to traditional chemical hair-strengthening treatments.

History is made as the FDA approves Mesoblast’s Ryoncil for paediatric graft-versus-host disease LTR Pharma firms up a compact with the Mens Health Downunder network The paperwork’s in! Orthocell ...

The Food and Drug Administration (FDA) announced in a statement Tuesday that it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease. The Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd ...

In this woodworking video I use a woodturning lathe to turn a decorative box from coloured veneer pieces cast in epoxy resin. Senate passes bill to stop shutdown, sending it to President Biden's ...

NOBLESVILLE, Ind. — The Noblesville Common Council approved the Morse Village project during Tuesday’s regular council meeting, giving the green light for the city to create over 600 new homes ...

Dec. 17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis, a type of eczema, in people aged 12 or older. Nemluvio is to be used with topical ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells. The FDA is reviewing data from the phase 3 ALLELE study (ClinicalTrials.gov ...

filed a petition on behalf of an activist group asking the Food and Drug Administration to suspend or withdraw approval of a polio vaccine for children. Attorney Aaron Siri filed the petition on ...

The FDA has approved cosibelimab under the brand name Unloxcyt for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC that’s not curable by surgery or ...

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. It is the first and only PD-L1 blocker approved to treat ...